Avidity Science - EMEA Revenue and Competitors

Thame, WI USA

Location

N/A

Total Funding

Research

Industry

Estimated Revenue & Valuation

  • Avidity Science - EMEA's estimated annual revenue is currently $5.4M per year.(i)
  • Avidity Science - EMEA's estimated revenue per employee is $91,800

Employee Data

  • Avidity Science - EMEA has 59 Employees.(i)
  • Avidity Science - EMEA grew their employee count by 7% last year.

Avidity Science - EMEA's People

NameTitleEmail/Phone
1
Head Sales and Marketing EMEAReveal Email/Phone
2
EVP, EMEA & Global Life Science SolutionsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.4M30-32%N/AN/A
#2
$0.3M6-25%N/AN/A
#3
$1.7M24-8%N/AN/A
#4
$57M447-4%N/AN/A
#5
$0.8M1318%N/AN/A
#6
$3.7M455%N/AN/A
#7
$5M5525%N/AN/A
#8
$5.4M597%N/AN/A
#9
$11.8M11617%N/AN/A
#10
$1.9M27-34%N/AN/A
Add Company

What Is Avidity Science - EMEA?

Avidity Science is a worldwide leader in water purification systems and laboratory equipment for scientific research and healthcare facilities. Since its inception in 1969, it has built a leadership position in the laboratory research market through a unique combination of water purification and delivery, environmental monitoring, and service solutions. Visit us at: www.AvidityScience.com.

keywords:N/A

N/A

Total Funding

59

Number of Employees

$5.4M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Avidity Science - EMEA News

2022-03-22 - Janssen Receives Positive CHMP Opinion Recommending ...

“At Janssen, we are resolute in our commitment to advance science and ... antibodies designed to confer high avidity against human BCMA.

2022-02-22 - Lyell CSO: New job is 'the missing piece' of his career; Orphazyme ...

At Lyell Immunopharma, he will have an abundance of scientific knowledge and ... Kim left the same position at Avidity Biosciences on Aug.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.1M627%N/A
#2
$13.9M63-6%N/A
#3
$19.5M1184%N/A
#4
$36.7M1367%N/A
#5
$81.2M2258%N/A